Translate Our Affiliations
Dana-Farber/Boston Children's is a teaching affiliate of Harvard Medical School.
Scott A. Armstrong, MD, PhD
- President, Dana-Farber/Boston Children's Cancer and Blood Disorders Center
- Chairman, Department of Pediatric Oncology
- Associate Chief, Division of Hematology/Oncology, Boston Children's Hospital
- David G. Nathan Professor of Pediatrics, Harvard Medical School
- Chief Research Strategy Officer
- Senior Vice President for Drug Discovery
Appointment Phone
- 888-733-4662
Fax
- 617-632-4367
General
Treatment Centers
Discipline
Clinical Interests
Hematologic malignancies
Location
Background
Board Certifications
Fellowship
Residency
Internships
Medical School
Biography
Scott A. Armstrong, MD PhD, was appointed Senior Vice President for Drug Discovery and Chief Research Strategy Officer in 2024, leading Dana-Farber's institutional research strategy focusing on our therapeutic discovery efforts. Dr. Armstrong became the President of Dana-Farber/Boston Children's Cancer and Blood Disorders Center in 2019 and has been Chairman of the Department of Pediatric Oncology at Dana-Farber Cancer Institute since 2016. He is also the David G. Nathan Professor of Pediatrics at Harvard Medical School and associate chief of the Division of Hematology/Oncology at Boston Children's Hospital.
Dr. Armstrong was previously director of the Center for Epigenetics Research at Memorial Sloan Kettering Cancer Center and Professor of Pediatrics at the Weil Cornell Medical College. He earned his medical degree and PhD from University of Texas Southwestern Medical School in 1996. After internship and residency training with the Boston Combined Residency Program (BCRP) at Boston Medical Center and Boston Children's Hospital, he completed a hematology/oncology fellowship at Dana-Farber/Boston Children's Cancer and Blood Disorders Center.
The major focus of Dr. Armstrong's career has been on delineating the biology of childhood cancers and the development of new therapeutic approaches for children with cancer. His research program has focused on the mechanisms of leukemia development and the relationship between leukemia and normal hematopoietic stem cells. Dr. Armstrong continues to direct a vigorous research program that focuses on development of the new therapeutics that target chromatin-based mechanisms, and he is actively involved in the development and translation of a number of new small molecule approaches that likely will be tested in clinical trials in the near future.